Novartis Stock
Novartis AG
Company data
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Country
- Switzerland
- CEO
- Vasant Narasimhan
- Employees
- 75,267
- Market cap
- $286.3 B
- IPO
- 07/11/1996
Novartis AG is a holding company engaged in the business of developing, manufacturing, and marketing healthcare products. The company's product portfolio focuses heavily on innovative prescription medicines, particularly in the areas of oncology, immunology, neuroscience, and cardiovascular diseases. These specialized…
Company description based on the data provider's company data, AI-assisted, created on 15/10/2026. Not investment advice.
Novartis stock: price history
1D
+0.2%
1W
+4.8%
1M
+8.6%
6M
-0.9%
YTD
+9.2%
1Y
+15.2%
2Y
+29.2%
5Y
+91.0%
10Y
+135.9%
Next earnings date
Next earnings date
27/10/2026 (in 10 days)
Volatility around earnings
~25% stronger price swings than usual
Novartis stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Ask the agents about Novartis
Analyst assessment of Novartis
PRICE TARGET LOW
US$136.00
CONSENSUS
US$146.00
MEDIAN
US$146.00
PRICE TARGET HIGH
US$156.00
0
STRONG BUY
6
BUY
17
HOLD
2
SELL
0
STRONG SELL
25
TOTAL · Hold
As of: 10/09/2026
Novartis stock metrics
P/E
22.95
P/B
6.92
EV/EBITDA
14.88
RETURN ON EQUITY
7.9%
NET MARGIN
22.7%
DEBT/EQUITY
1.18
DIVIDEND YIELD
3.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
96.3%
FLOAT SHARES
1,830,370,418
AVG. DAILY VOLUME (30D)
2,207,021
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: +0.2%
Forums (Reddit)
Institutional holders
Dividends & Stock splits
Dividends
Stock splits
Smart Money
Register for free
Register now to see which funds are invested
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Comparable stocks
Frequently asked questions about Novartis stock
What does Novartis do?
Novartis AG is a company in the Healthcare sector, Drug Manufacturers - General industry, headquartered in Switzerland.
The CEO is Vasant Narasimhan, the company employs around 75,267 people.
The IPO was on 07/11/1996; the stock trades on NYSE under the ticker NVS.
What do analysts say about Novartis stock?
25 analysts rate the stock, the consensus is Hold (as of 10/09/2026).
The average price target is US$146.00, ranging from US$136.00 to US$156.00, with a median of US$146.00.
This is an external assessment, not a statement by Market Jury.
When does Novartis report next?
The next earnings date is 27/10/2026.
Around past earnings, price swings were roughly 25% stronger than usual.
Does Novartis pay a dividend?
Yes. The last dividend was US$4.74 per share, ex-date 11/03/2026, paid on 16/03/2026.
The dividend yield is 3.0% (as of 30/06/2026).
Which stocks are comparable to Novartis?
Comparable stocks include Roche Holding, Eli Lilly and Company, Johnson & Johnson, AbbVie, Merck &, Amgen, Gilead Sciences and Pfizer.
How can I get Novartis stock analyzed?
Clicking "Analyze stock" lets five strategies assess Novartis against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.